- Lillys Imlunestrant, an Oral SERD, Significantly Improved Progression . . .
Imlunestrant is an orally administered, brain penetrant, pure ER antagonist that delivers continuous ER target inhibition Imlunestrant is also being investigated in the adjuvant setting in people with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence
- Imlunestrant - Wikipedia
Imlunestrant is an experimental selective estrogen receptor degrader developed by Eli Lilly and Company for the treatment of some types of breast cancer [1][2][3]
- Imlunestrant Alone or With Abemaciclib: An All-Oral Targeted Therapy . . .
As combination therapy, imlunestrant plus abemaciclib improved progression-free survival by 43% vs imlunestrant alone in all patients regardless of ESR1 mutation status
- Imlunestrant Stops Progression of ER+, HER2- Advanced Breast Cancer . . .
Imlunestrant is part of a class of drugs called selective estrogen receptor degraders (SERDs) These drugs bind with estrogen receptors to stop estrogen from attaching to cancer cells and fueling their growth They also degrade the receptor protein
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
- Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor . . .
Significance: Imlunestrant, a next-generation, brain-penetrant oral ERα degrader, displays potent activity in ESR1 wild-type and mutant breast cancer, enhances combination activity with standard-of-care agents, and inhibits growth of ER + intracranial tumors
- Imlunestrant a next-generation oral SERD overcomes
We investigated the preclinical efficacy of imlunestrant, an oral selective ER degrader, in ER-positive breast cancer preclinical models, including models harboring the Y537S ESR1 mutation, an activating mutation
- Clinical Trial: Imlunestrant Alone or in Combination for ER+, HER2 . . .
Description: Researchers are conducting a phase 3 trial to compare imlunestrant alone to standard hormone therapy or imlunestrant plus abemaciclib in patients with estrogen receptor
|